Please enable JS




The eISF, or electronic Investigator Site File, is the digital version of the paper-based investigator site file (ISF). It enables the collection in digital form of essential documents that demonstrate a clinical trial was conducted in accordance with Good Clinical Practice (GCP) guidelines, as well as regulatory and sponsor requirements. These documents include the protocol, informed consent forms, study reports, lab results, and other documentation related to the trial.

Leads to this page

The eISF is stored in a secure, web-based system that is accessible to authorized personnel only

The use of eISFs has several advantages over paper-based ISFs :
• efficiency in document management
• increases accuracy and completeness of data
• enhances security of sensitive information
• facilitates remote monitoring of study sites
• real-time data access and sharing between sites, sponsors, and regulatory agencies

Theuse of eISFs represents a significant step forward in the conduct of clinical research, enabling faster and more efficient trial management while ensuring compliance with regulatory and ethical standards.


telemedecine technologies news

14th Meeting of the CleanWeb™ Users Club

May 30, 2024

June 18, 2024 – 2:00 PM – 3:00 PM CEST Join us for the 14th meeting of the CleanWeb™ Users Group. This webinar is free and open to all our users. This afternoon traditionally serves as an opportunity to review the latest features developed for our users and to present upcoming developments. During this webinar, […]

telemedecine technologies news

Yes, Agile Can Work in Medtech

May 30, 2024

Med City News Three tips to succeed in a highly regulated environment. Medical devices take multiple years and millions of dollars to bring to market. Regulations play a huge role: medtech manufacturers must meet a range of requirements to get devices approved – or risk wasting their investment. The high cost of failure encourages many […]

telemedecine technologies news

Integrated Biosciences and Illumina Ventures Labs Collaborate on Novel Therapeutics Targeting the Transcriptome

May 30, 2024

BioPharm International The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery. Integrated Biosciences, a biotechnology company that uses synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, announced on May 28, 2024, that it is collaborating with Illumina Ventures Labs to create novel therapeutics targeting the […]